BASIS OF PRESENTATION AND NATURE OF BUSINESS (Details Narrative) |
1 Months Ended | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|---|
Aug. 31, 2022
USD ($)
Integer
|
Sep. 30, 2022
USD ($)
|
Sep. 30, 2021
USD ($)
|
Sep. 30, 2022
USD ($)
Integer
|
Sep. 30, 2021
USD ($)
|
|
Patents owned by the Company | Integer | 96 | ||||
Gain on its ILiAD investment | $ 3,727,000 | $ 3,727,000 | |||
Gain on ILiAD conversion of convertible note | $ 271,000 | $ 271,000 | |||
I Li A D Biotechnologies L L C [Member] | |||||
Aggregate investment amount | $ 7,000,000 | ||||
Patents owned by ILiAD | Integer | 62 |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Number of entity's patents that another entity was found to have infringed. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Amount of realized and unrealized gain (loss) on investment. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all investments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|